Is the price fair?
What BCRX's price assumes
BioCryst Pharmaceuticals, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 2.60× revenue.
2.60
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 16%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.5%
- Growth the price implies
- −11%
Growth the price implies · The price pays for −11% free cash flow growth a year for a decade; revenue has grown +45% a year over the last three.
- EV / sales
- 2.86
EV / sales
Details›
- EV / EBIToperating margin −33%: the multiple describes the denominator
- not meaningful
- EV / sales2026-Q1
- 2.86
- Free cash flow, trailing twelve months
- $373M
- Market capitalisation
- $2.28B
- 3-year revenue growth
- +45%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - Specialty & Generic
Ranks #2 of 28 by Smart Score